Parkman Healthcare Partners LLC purchased a new position in shares of Envista Holdings Corporation (NYSE:NVST – Free Report) in the 2nd quarter, Holdings Channel.com reports. The fund purchased 553,916 shares of the company’s stock, valued at approximately $14,596,000. Envista comprises about 1.5% of Parkman Healthcare Partners LLC’s portfolio, making the stock its 27th largest position.
Other large investors also recently modified their holdings of the company. Dimensional Fund Advisors LP grew its holdings in shares of Envista by 1.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 9,780,948 shares of the company’s stock worth $248,130,000 after purchasing an additional 152,488 shares during the period. Alliancebernstein L.P. raised its holdings in Envista by 34.0% in the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after buying an additional 1,547,656 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Envista by 341.5% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,858,293 shares of the company’s stock valued at $72,515,000 after buying an additional 2,210,847 shares during the period. Quantinno Capital Management LP lifted its position in Envista by 38.8% during the first quarter. Quantinno Capital Management LP now owns 2,694,970 shares of the company’s stock valued at $68,371,000 after buying an additional 753,474 shares in the last quarter. Finally, Millennium Management LLC lifted its position in Envista by 1,442.7% during the fourth quarter. Millennium Management LLC now owns 2,420,615 shares of the company’s stock valued at $52,552,000 after buying an additional 2,263,712 shares in the last quarter.
Envista Trading Up 0.5%
Shares of NVST opened at $27.34 on Tuesday. The company has a market capitalization of $4.39 billion, a P/E ratio of 47.15, a P/E/G ratio of 1.30 and a beta of 0.86. Envista Holdings Corporation has a one year low of $18.77 and a one year high of $30.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.43. The stock has a 50-day moving average price of $26.95 and a 200 day moving average price of $26.33.
Analysts Set New Price Targets
Several research firms have recently issued reports on NVST. Mizuho set a $29.00 price objective on shares of Envista in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Envista from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, August 6th. Barclays decreased their price target on shares of Envista from $34.00 to $32.00 and set an “overweight” rating for the company in a research report on Thursday, June 11th. Piper Sandler reiterated a “neutral” rating and issued a $28.00 price target (up from $26.00) on shares of Envista in a report on Thursday, August 6th. Finally, Robert W. Baird set a $34.00 price objective on Envista in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.31.
Get Our Latest Report on Envista
Insider Buying and Selling
In other Envista news, SVP Mischa Reis sold 8,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $27.50, for a total transaction of $220,000.00. Following the transaction, the senior vice president owned 27,321 shares of the company’s stock, valued at $751,327.50. This trade represents a 22.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is currently owned by corporate insiders.
Envista Profile
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Read More
- Five stocks we like better than Envista
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding NVST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Envista Holdings Corporation (NYSE:NVST – Free Report).
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
